The spike glycoprotein of SARS-CoV-2 engages with human ACE 2 to facilitate infection.
Here, we describe an alpaca-derived heavy chain antibody fragment (VHH), saRBD-1, that …

Despite unprecedented global efforts to rapidly develop SARS-CoV-2 treatments, in order to
reduce the burden placed on health systems, the situation remains critical. Effective …

SARS-CoV-2 enters host cells through an interaction between the spike glycoprotein and
the angiotensin converting enzyme 2 (ACE2) receptor. Directly preventing this interaction …

Despite unprecedented global efforts to rapidly develop SARS-CoV-2 treatments, in order to
reduce the burden placed on health systems, the situation remains critical. Effective …

Without an effective prophylactic solution, infections from SARS-CoV-2 continue to rise
worldwide with devastating health and economic costs. SARS-CoV-2 gains entry into host …

Cellular entry of SARS-CoV-2 requires the binding between the receptor-binding domain
(RBD) of the viral Spike protein and the cellular angiotensin-converting enzyme 2 (ACE2) …

Neutralizing antibodies are important for immunity against SARS-CoV-2 and as therapeutics
for the prevention and treatment of COVID-19. Here, we identified high-affinity nanobodies …

Coronaviruses cause severe human viral diseases including SARS, MERS and COVID-19.
Most recently SARS-CoV-2 virus (causing COVID-19) has led to a pandemic with no …

SARS-CoV-2 and its variants continue to threaten public health. Nanobodies that block the
attachment of the RBD to host cell angiotensin-converting enzyme 2 (ACE2) represent …

Antibodies binding to the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
spike have therapeutic promise, but emerging variants show the potential for virus escape …